SCHEMBL2797910

SCHEMBL2797910

OC(c1cccc(Br)c1)P(O)O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 4/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2D6 P10635 3/20 0.37
SLC6A3 Q01959 3/20 0.37
KCNH2 Q12809 1/20 0.37
CA1 P00915 1/20 0.37
MMP2 P08253 1/20 0.37
CA14 Q9ULX7 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
SLC18A3 Q16572 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
C1S P09871 1/20 0.35
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5911692 0.78 CYP3A4 (0.47) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL5872085 0.78 IDO1 (0.47) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL31476387 0.78 IDO1 (0.47) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL241692 0.78 IDO1 (0.47) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL5773097 0.78 CYP3A4 (0.47) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL3632448 0.78 IDO1 (0.41) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL27689825 0.76 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL15456282 0.76 IDO1 (0.46) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL6204787 0.74 IDO1 (0.44) IDO1TDO2SLC6A2SLC6A4CYP3A4
SCHEMBL7673890 0.74 IDO1 (0.44) IDO1TDO2SLC6A2SLC6A4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168194-A1 Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase WYETH LLC (US) 2010-07-01 US disclosed
EP-2144884-A2 AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE Wyeth a Corporation of the State of Delaware (US) 2010-01-20 EP disclosed
WO-2008118379-A2 AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF β-SECRETASE WYETH (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168194-A1 Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase BACE1, BACE2, APP IDO1 4416/4885TDO2 4484/4885SLC6A2 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.